TPE:2330 10 July 2026

July 10, 2026, 9:04 AM EDT. DexCom (DXCM) sales rose 16.1%. Still, shares fell 12.8% as its price-to-sales multiple tumbled 27% over the past year. Patient growth has flattened in the U.S., raising doubts over how long DexCom can keep this pace up. Management guided to 11-13% revenue growth for the year and is waiting on Medicare approval that could bring in more Type 2 diabetes patients. Investors are wary, pricing in a slower or smaller boost from that potential catalyst. The gap between management's guidance and market concern is plain in the stock's slide.